



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Friday, 25 June 2021

Bombay Stock Exchange
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers, Dalal Street,
Fort, Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No.C/1, G
Block Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir / Madam,

Sub: Intimation U/R 30 of the SEBI(Listing Obligation & Disclosure Requirements) Regulations- 2015

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Limited receives in-principle approval from Defence Research & Development Organisation (DRDO) for technology transfer, manufacture and supply of 2-Deoxy-D-Glucose (2DG)

Shilpa Medicare Limited (Shilpa), a research-led global integrated pharmaceutical company, today hereby announces that it has received an in-principle approval from Defence Research & Development Organisation (DRDO) to manufacture and sale of 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for COVID-19 patients in the country. Shilpa Medicare Limited is only the second company in India to have entered into similar arrangement with DRDO.

Shilpa has been continuously striving to contribute towards the fight against COVID-19 and this is yet another step by Shilpa after its recently announced arrangement for manufacture and supply of Sputnik V vaccine.

This is for your information and doing the needful.

With Regards,

V V Krishna Chaitanya
Company Secretary & Compliance Officer

